Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. [electronic resource]
Producer: 20190823Description: 1075-1085 p. digitalISSN:- 1532-1827
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- BRCA1 Protein -- genetics
- BRCA2 Protein -- genetics
- Capsules
- Cystadenocarcinoma, Serous -- drug therapy
- Disease-Free Survival
- Double-Blind Method
- Female
- Humans
- Maintenance Chemotherapy
- Middle Aged
- Mutation
- Neoplasm Recurrence, Local -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Platinum -- administration & dosage
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.